Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies

NCT ID: NCT02182245

Last Updated: 2025-01-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-10-01

Brief Summary

The primary objectives of this trial were to determine the safety, tolerability, and MTD of BIBF 1120 when added to standard therapy with carboplatin and paclitaxel

Conditions

Genital Neoplasms, Female

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Combination Therapy

Group Type: EXPERIMENTAL

BIBF 1120

Intervention Type: DRUG

Paclitaxel

Intervention Type: DRUG

Carboplatin

Intervention Type: DRUG

Monotherapy

Group Type: EXPERIMENTAL

BIBF 1120

Intervention Type: DRUG

Interventions

BIBF 1120

Intervention Type: DRUG

Paclitaxel

Intervention Type: DRUG

Carboplatin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Female patients with the following histologically confirmed advanced gynaecological malignancies: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma or vulvular carcinoma
• Metastatic disease or locally advanced disease that is not resectable with curative intention
• Indication for combination chemotherapy with paclitaxel/carboplatin as judged by the investigator
• Age 18 years or older
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Life expectancy of at least 6 months
• Written informed consent that is not consistent with ICH-GCP (International Conference on Harmonisation - Good Clinical Practice) guidelines and local requirements

Exclusion Criteria

• Participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study
• Radiotherapy within 4 weeks before the start of therapy
• Chemotherapy, immunotherapy or hormonal therapy (with the exception of hormonal replacement therapy) within 4 weeks before the start of the therapy
• Patients with germ cell tumours, early stage ovarian cancer (Fédération Internationale de Gynécologie et d'Obstétrique [FIGO] stage I-IIA), primary cervical cancer (FIGO I-III), primary endometrial cancer (FIGO I-III) or borderline tumours
• Patients with known brain metastases
• Symptomatic bowel obstruction or known or suspected malabsorption
• Patients with pericardial effusion which is haemodynamically relevant
• Other malignancy diagnosed within the past 5 years (other than non-melanomatous skin cancer or cervical carcinoma in situ)
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study medication
• History of haemorrhagic or thrombotic event (including transient ischemic attacks) in the past 6 months
• Concurrent therapeutic anticoagulation or anti-platelet therapy (except chronic low dose daily acetylsalicylic acid <300 mg)
• Major injuries and surgeries within the past 3 weeks, planned surgical procedures during the trial, incomplete wound healing
• Known hypersensitivity to paclitaxel, carboplatin, BIBF 1120 or any of their excipients or vehicles such as polyoxyethylated castor oil
• Clinically significant peripheral polyneuropathy (>CTCAE grade 1) which precludes therapy with paclitaxel
• Absolute neutrophil count (ANC) <1500/μL, platelet count <100000/μL, or haemoglobin <9 mg/dL
• Total bilirubin >1.5 mg/dL (26 μmol/L), ALT (Alanine aminotransferase) and/or AST (Aspartate aminotransferase) >1.5 x the upper limit of normal (ULN)
• Serum creatinine >1.5 mg/dL (>132 μmol/L)
• Persistent gross haematuria
• Pregnancy or breast feeding
• Women with childbearing potential and who are sexually active and unwilling to use a medically acceptable method of contraception (oral contraceptive, diaphragm with spermicide, intrauterine device, condom with spermicide)
• Known or suspected active drug or alcohol abuse

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Related Links

https://www.mystudywindow.com

Related Info

Other Identifiers

1199.6

Identifier Type: -

Identifier Source: org_study_id